In 1943, biochemist Albert Hoffman accidentally ingested a chemical that he had synthesized from a fungus and discovered that it created hallucinations. The mind-bending chemical was lysergic acid ...

University of Auckland researchers report that an 8-week, twice-weekly LSD microdosing regimen for major depressive disorder was feasible and well-tolerated, with Montgomery-Åsberg Depression Rating ...

Before Mojang released Vibrant Visuals on Minecraft Bedrock, they released support for shaders and high-fidelity textures using RTX technology by Nvidia. After RTX (or ray tracing) support was ...

A new study suggests that lysergic acid diethylamide (LSD), also known as acid, could reduce anxiety. This marks the first-ever trial to evaluate the safety and efficacy of MM120 (a pharmaceutical ...

A single dose of an investigational lysergic acid diethylamide (LSD)-based medication known as MM120 (lysergide D-tartrate, Mind Medicine Inc [MindMed]) was associated with a rapid and significant ...

A recent study by MindMed reveals that LSD could be a potential treatment for anxiety. A single dose significantly reduced anxiety symptoms in individuals with generalized anxiety disorder, with ...

The study enrolled 198 adults with anxiety at 22 sites across the U.S. Once a symbol of 1960s counterculture, the drug lysergic acid diethylamide, commonly known as LSD, is emerging from research labs ...

LSD reduced symptoms of anxiety in a midstage study published Thursday, paving the way for additional testing and possible medical approval of a psychedelic drug that has been banned in the U.S. for ...

A single dose of the psychedelic drug LSD seems to reduce anxiety without lasting side effects. “Ours is the first modern trial to look specifically at LSD, or any psychedelic, for generalised anxiety ...

A mid-stage study of a pharmaceutical version of the psychedelic LSD reported the drug might help alleviate anxiety symptoms for up to three months, advancing a potential treatment for the most common ...

The Studio LSD IPO witnessed a fairly strong response from investors, closing with an overall subscription of 3.23 times. The issue received 4.21 crore bids against 1.30 crore shares on offer.

Paul McCartney isn’t known as the most well-versed of his peers when it comes to drugs. He and his Beatles bandmates did their fair share, but they didn’t end up with the same kind of reputation as ...